Shreya Chatterjee

“Could you explain a bit more on what is happening on Lorman and Cross and that you have also entered into ethnic and footwear segments this time. So, what are you doing there, over there?”

“Would it be possible to give some color as to how the different segments of the business, like Pharma, CDMO, SpecChem plus ActChem, and then API Plus and the Nishkeg as well, will evolve over the next two to three quarters, as in how many molecules that are going to come in the pipeline and all?”

“For the pharma and nutrition segment, the new molecules that you mentioned, Could you just give a color as to how, like, what's the margin or the unique pricing or the unique economic profile of your current portfolio versus your new molecules?”

“My first question is just confirming the fact that you had mentioned that there would be four commercial molecule launch in FI27. So, I guess two molecules have already launched.”

“My question would be that on your four verticals, would it be possible to give out the margin profile of each of the verticals? And going into the future, which vertical will grow the highest?”